How is centronuclear myopathy diagnosed when symptoms are mild?

Diagnosis usually starts with a detailed clinical history and physical exam, noting muscle weakness patterns and any facial or respiratory involvement. A muscle biopsy is the gold standard; it shows centrally located nuclei in muscle fibers. If a biopsy is inconclusive, genetic testing for known mutations (e.g., DNM2, BIN1, RYR1) can confirm the diagnosis.

What are the best strategies to manage breathing problems in patients with centronuclear myopathy?

Regular pulmonary function tests help monitor lung capacity. Non‑invasive ventilation (e.g., BiPAP) can be started before overt respiratory failure. Chest physiotherapy, incentive spirometry, and early referral to a pulmonologist are key to prolonging respiratory function and preventing infections.

Is there a genetic test that can predict the severity or progression of centronuclear myopathy?

While specific genotype‑phenotype correlations are still being studied, certain mutations (e.g., in the DNM2 gene) are associated with a more severe, early‑onset form. Genetic counseling can explain the likelihood of disease severity, inheritance patterns, and the options for prenatal or pre‑implantation genetic diagnosis for future pregnancies.===

Can physical therapy improve muscle strength or slow muscle wasting in centronuclear myopathy?

Yes, a tailored exercise program focusing on low‑impact, resistance‑based activities can help maintain muscle tone and improve functional mobility. Avoiding over‑exertion is crucial, as excessive fatigue can accelerate weakness. A multidisciplinary team—including physiatrists, occupational therapists, and speech therapists—can create a comprehensive plan.

Centronuclear Myopathy

Centronuclear myopathy is a rare genetic disorder that causes progressive muscle weakness and wasting due to the abnormal central placement of nuclei in muscle cells, with symptoms ranging from mild to severe and varying even within families.

Overview

Centronuclear myopathy is a condition characterized by muscle weakness (myopathy) and wasting in the skeletal muscles, which are the muscles used for movement. The severity of centronuclear myopathy varies among affected individuals, even among members of the same family.

People with centronuclear myopathy begin experiencing muscle weakness at any time from birth to early adulthood. The muscle weakness slowly worsens over time and can lead to delayed development of motor skills, such as crawling or walking; muscle pain during exercise; and difficulty walking. Some affected individuals may need wheelchair assistance as the muscles atrophy and weakness becomes more severe. In rare instances, the muscle weakness improves over time.

Some people with centronuclear myopathy experience mild to severe breathing problems related to the weakness of muscles needed for breathing. People with centronuclear myopathy may have droopy eyelids and weakness in other facial muscles, including the muscles that control eye movement. People with this condition may also have foot abnormalities, a high arch in the roof of the mouth, and abnormal side-to-side curvature of the spine. Rarely, individuals with centronuclear myopathy have a weakened heart muscle, disturbances in nerve function (neuropathy), or intellectual disability.

A key feature of centronuclear myopathy is the displacement of the nucleus in muscle cells, which can be viewed under a microscope. Normally the nucleus is found at the edges of the rod-shaped muscle cells, but in people with centronuclear myopathy the nucleus is located in the center of these cells. How the change in location of the nucleus affects muscle cell function is unknown.

Frequency

Centronuclear myopathy is a rare condition; its exact prevalence is unknown.

Causes & Risk Factors

is most often caused by mutations in the DNM2, BIN1, or TTN gene. The proteins produced from the DNM2 and BIN1 genes are involved in endocytosis, a process that brings substances into the cell. The protein produced from the BIN1 gene plays an additional role in the formation of tube-like structures called transverse tubules (or T tubules), which are found within the membrane of muscle fibers. These tubules help transmit the electrical impulses necessary for normal muscle tensing (contraction) and relaxation. The protein produced from the DNM2 gene also regulates the , which makes up the muscle fiber's structural framework. DNM2 and BIN1 gene mutations lead to abnormal muscle fibers that cannot contract and relax normally, resulting in muscle weakness.

The TTN gene provides instructions for making a protein called titin that is an essential component of muscle fiber structures called . Sarcomeres are the basic units of muscle contraction; they are made of proteins that generate the mechanical force needed for muscles to contract. TTN gene mutations decrease or alter titin's activity in muscle fibers. It is unclear how these mutations lead to centronuclear myopathy, but it is likely that the altered protein cannot interact with other proteins in the sarcomere, leading to dysfunction of the sarcomere. Abnormal sarcomeres prevent muscle fibers from contracting and relaxing normally, resulting in muscle weakness.

Some people with centronuclear myopathy do not have identified mutations in the DNM2, BIN1, or TTN genes. Mutations in other genes associated with this condition are found in a small percentage of cases. Some males with signs and symptoms of severe centronuclear myopathy may have a condition called X-linked myotubular myopathy, which is similar to centronuclear myopathy, and is often considered a subtype of the condition, but has a different genetic cause. In some people with centronuclear myopathy, the cause of the disorder is unknown. Researchers are looking for additional genes that are associated with centronuclear myopathy.

Learn more about the genes associated with Centronuclear myopathy

BIN1
DNM2
RYR1
TTN

Additional Information from NCBI Gene:

CCDC78
SPEG

Inheritance

When centronuclear myopathy is caused by mutations in the DNM2 gene, it is inherited in an , which means one copy of the altered DNM2 gene in each cell is sufficient to cause the disorder. Rarely, BIN1 gene mutations that are inherited in an autosomal dominant pattern can cause centronuclear myopathy.

Centronuclear myopathy caused by TTN gene mutations and most cases caused by BIN1 gene mutations are inherited in an , which means both copies of the gene in each cell have mutations. The parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Other cases of centronuclear myopathy that are not caused by these genes are typically inherited in an autosomal recessive manner, although some follow an autosomal dominant pattern.

Other Names for This Condition

CNM
Myopathy, centronuclear

Additional Information & Resources

Genetic Testing Information

Genetic Testing Registry: Centronuclear myopathy
Genetic Testing Registry: Congenital myopathy with internal nuclei and atypical cores
Genetic Testing Registry: Myopathy, centronuclear, 5

Genetic and Rare Diseases Information Center

Centronuclear myopathy

Patient Support and Advocacy Resources

National Organization for Rare Disorders (NORD)

Clinical Trials

ClinicalTrials.gov

Catalog of Genes and Diseases from OMIM

MYOPATHY, CENTRONUCLEAR, 1; CNM1
MYOPATHY, CENTRONUCLEAR, 2; CNM2
MYOPATHY, CENTRONUCLEAR, 4; CNM4
MYOPATHY, CENTRONUCLEAR, 5; CNM5

Scientific Articles on PubMed

Agrawal PB, Pierson CR, Joshi M, Liu X, Ravenscroft G, Moghadaszadeh B, Talabere T, Viola M, Swanson LC, Haliloglu G, Talim B, Yau KS, Allcock RJ, Laing NG, Perrella MA, Beggs AH. SPEG interacts with myotubularin, and its deficiency causes centronuclear myopathy with dilated cardiomyopathy. Am J Hum Genet. 2014 Aug 7;95(2):218-26. doi: 10.1016/j.ajhg.2014.07.004. Epub 2014 Jul 31.
Bohm J, Biancalana V, Malfatti E, Dondaine N, Koch C, Vasli N, Kress W, Strittmatter M, Taratuto AL, Gonorazky H, Laforet P, Maisonobe T, Olive M, Gonzalez-Mera L, Fardeau M, Carriere N, Clavelou P, Eymard B, Bitoun M, Rendu J, Faure J, Weis J, Mandel JL, Romero NB, Laporte J. Adult-onset autosomal dominant centronuclear myopathy due to BIN1 mutations. Brain. 2014 Dec;137(Pt 12):3160-70. doi: 10.1093/brain/awu272. Epub 2014 Sep 25.
Ceyhan-Birsoy O, Agrawal PB, Hidalgo C, Schmitz-Abe K, DeChene ET, Swanson LC, Soemedi R, Vasli N, Iannaccone ST, Shieh PB, Shur N, Dennison JM, Lawlor MW, Laporte J, Markianos K, Fairbrother WG, Granzier H, Beggs AH. Recessive truncating titin gene, TTN, mutations presenting as centronuclear myopathy. Neurology. 2013 Oct 1;81(14):1205-14. doi: 10.1212/WNL.0b013e3182a6ca62. Epub 2013 Aug 23.
Jungbluth H, Gautel M. Pathogenic mechanisms in centronuclear myopathies. Front Aging Neurosci. 2014 Dec 19;6:339. doi: 10.3389/fnagi.2014.00339. eCollection 2014.
Jungbluth H, Wallgren-Pettersson C, Laporte J. Centronuclear (myotubular) myopathy. Orphanet J Rare Dis. 2008 Sep 25;3:26. doi: 10.1186/1750-1172-3-26.
Majczenko K, Davidson AE, Camelo-Piragua S, Agrawal PB, Manfready RA